Home › Cancer types › Lung Cancer

Just diagnosed with lung cancer?

By the Cancer Clues team · Last updated 1 November 2026 · How we grade treatments

The honest numbers

Statistics describe groups, never one person — and in lung cancer they are moving in the right direction fast enough that older numbers you may find elsewhere are already out of date.

• About 229,000 US diagnoses expected in 2026 [1].
• Five-year relative survival (patients diagnosed 2016–2022): ~29% overall — 66% when caught localized, 10.5% after distant spread [1].
• The trend is the story: overall five-year survival has roughly doubled since the mid-1990s (15% → 28%), and distant-stage survival rose from 2% to 10% — a change driven by targeted drugs and immunotherapy, not just less smoking [2][3]. Death rates are currently falling about 4% per year [1].
• About 10–15% of cases are small-cell lung cancer, a different disease with different treatment and, honestly, less progress so far [3][4].

What's actually proven

• Biomarker testing first. For advanced non-small-cell lung cancer, the tumor is tested for genetic errors (EGFR, ALK, ROS1, KRAS and more) and for PD-L1. A targetable error means a pill (like osimertinib for EGFR) usually beats chemotherapy; high PD-L1 points to immunotherapy. Waiting a few days for these results is almost always worth it [4][5].
• Early stage: surgery (usually lobectomy) is the curative backbone; precisely targeted radiation (SBRT) is a real option when surgery isn't [4].
• Immunotherapy around surgery — now standard for many resectable cases: giving immunotherapy with chemo before and after surgery improves outcomes (FDA approvals in 2024) [6].
• Stage III and beyond: combinations of chemo, radiation, immunotherapy and targeted drugs, sequenced by specialists — this is where a thoracic tumor board earns its keep [4][5].

Stage-by-stage depth from the sources doctors use: NCI's patient guides for non-small-cell and small-cell disease [4], and the NCCN patient guidelines [5].

What people ask about (from our graded library)

• Fenbendazole — the famous Joe Tippens story was a lung-cancer story, which is why it circulates hardest here. The honest version: he was simultaneously in a clinical trial, no human trial of fenbendazole has ever been run, and the published liver-injury case was a lung-cancer patient following the protocol [7].
• High-dose IV vitamin C — graded Promising: a 38-patient lung-cancer trial alongside chemotherapy showed better-than-expected response rates, but it had no control group — genuinely interesting, far from proven [8].
• Cannabis & CBD — can help hard-to-treat chemo nausea (prescription forms are approved); no evidence it treats the cancer; smoking anything is a bad idea with lung disease.
• Browse the full graded library before adding anything to treatment.

Does the hospital matter?

For lung surgery, volume matters: analyses pooling many studies find lower post-operative death rates and better survival at higher-volume surgical centers — in one large cohort, in-hospital mortality after resection was about 1% at high-volume centers versus 3% at low-volume ones [9]. For advanced disease, the “where” question is different: it's about access to comprehensive biomarker testing, the full shelf of targeted drugs, and clinical trials. A major center consult — even one remote second opinion — can set the plan your local team then delivers. We organize exactly that.

What's new (and real)

• Immunotherapy around surgery (2024 FDA approvals) — resectable lung cancer is now often treated with chemo-immunotherapy before surgery [6].
• A new drug class, antibody-drug conjugates: datopotamab deruxtecan was approved in June 2025 for certain pretreated EGFR-mutated cancers — think of it as chemotherapy delivered by GPS [10].
• Screening works and is scandalously underused: annual low-dose CT is recommended for ages 50–80 with a heavy smoking history — yet fewer than one in five eligible Americans gets it. If that's you or family, this one scan is the highest-value test in this guide [11].

Questions for your oncologist (bring this list)

1. Has my tumor had full biomarker testing (EGFR, ALK, ROS1, KRAS, PD-L1 and the rest)? Can treatment wait for the results?
2. What stage am I exactly, and is surgery or targeted radiation an option?
3. If my cancer has a targetable mutation: which pill is first, and what's the plan when it stops working?
4. Was my case discussed by a thoracic tumor board?
5. Which clinical trials fit my biomarkers — here or elsewhere?

Common questions